A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
ConditionSolid Tumor
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMabwell (Shanghai) Bioscience Co., Ltd.
About this trial
This study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.
Eligibility criteria
Qualifiers
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Life expectancy of at least 3 months as assessed by the Investigator.
Phase 1b: Histologically or cytologically confirmed locally advanced or metastatic solid tumor, progressive after last treatment received and who progressed on or after standard therapies or intolerant to approved therapies or who lack of effient standard therapies. Phase 2: Histologically or cytologically confirmed locally advanced or metastatic selected advanced solid tumors.
Measurable or evaluable disease by RECIST v1.1.
Disqualifiers
Have other prior malignancies within 3 years before the first administration.
Known central nervous system metastatic disease or carcinomatous meningitis except for treated and stable brain metastases.
Have significant, uncontrolled, or active cardiovascular disease.
Known history of COPD, or intestinal lung disease, or other respiratory diseases requring inpatient treatments within 4 weeks prior to first administration.
Trial design
Treatments tested in this trial
- 7MW3711
- JS207
- Cisplatin
- Carboplatin
Treatment groups
280 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov